The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting: Reflecting a Changing mRCC Treatment Landscape
暂无分享,去创建一个
V. Grünwald | J. Bedke | P. Goebell | M. Schostak | M. Bögemann | M. Welslau | Elisa Degenkolbe | Stefanie Witecy | C. Doehn | R. Ehness | Thomas Wolf
[1] U. Capitanio,et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. , 2022, European urology.
[2] Kazuhiko Yoshida,et al. Prognostic Impact of Trial-Eligibility Criteria in Patients with Metastatic Renal Cell Carcinoma , 2021, Urologia Internationalis.
[3] V. Grünwald,et al. Sequential treatment with pazopanib followed by nivolumab in patients with renal cell carcinoma: Updated interim results of the non-interventional study PAZOREAL. , 2020 .
[4] P. Conte,et al. Real-World Evidence in Oncology: Opportunities and Limitations. , 2019, The oncologist.
[5] V. Grünwald,et al. Sequential treatment with pazopanib (PAZO) followed by nivolumab (NIVO) in patients with advanced or metastatic renal cell carcinoma (mRCC): Third interim results of the non-interventional study PAZOREAL. , 2019, Journal of Clinical Oncology.
[6] I. Chirivella,et al. Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma , 2018, BMC Pharmacology and Toxicology.
[7] R. Motzer,et al. Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial , 2018, Journal of Hematology & Oncology.
[8] J. Bedke,et al. Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL. , 2018 .
[9] R. Figlin,et al. Targeted therapies for renal cell carcinoma , 2017, Nature Reviews Nephrology.
[10] M. Staehler,et al. Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials—Analyses From the German Clinical RCC Registry , 2017, Clinical genitourinary cancer.
[11] U. Vaishampayan,et al. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms , 2017, Current Treatment Options in Oncology.
[12] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[13] S. Welsh,et al. Pazopanib for the treatment of renal cell carcinoma. , 2015, Future oncology.
[14] C. Sternberg,et al. An Open-Label Extension Study to Evaluate Safety and Efficacy of Pazopanib in Patients with Advanced Renal Cell Carcinoma , 2014, Oncology.
[15] C. Porta,et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Reeves,et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.
[17] P. Spiess,et al. The prospects of pazopanib in advanced renal cell carcinoma , 2013, Therapeutic advances in urology.
[18] Lauren McCann,et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. , 2013, European journal of cancer.
[19] Han Yong Choi,et al. The epidemiology of renal cell carcinoma. , 2011, European urology.
[20] G. Bonsel,et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) , 2011, Quality of Life Research.
[21] Lorenzo Marconi,et al. EAU guidelines on renal cell carcinoma: 2014 update. , 2010, European urology.
[22] R. Amado,et al. An indirect comparison analysis of pazopanib versus other agents in metastatic renal cell carcinoma (mRCC). , 2010 .
[23] C. Porta,et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] C. Sternberg,et al. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] P. Choyke,et al. Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics , 2007, Clinical Cancer Research.
[26] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[27] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[28] J. Himmelfarb,et al. Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib , 2014 .
[29] R. Motzer,et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.